ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 1st, 2023 • NRX Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this "Agreement") is made and entered into as of November 12, 2022 (the "Execution Date"), by and between NRx Pharmaceuticals, Inc., a Delaware corporation ("NRx Pharma"), and its wholly-owned subsidiary, NeuroRx, Inc., a Delaware corporation ("NeuroRx", and collectively with NRx Pharma, "NRx"), on the one hand, and RELIEF THERAPEUTICS Holding SA, a corporation organized under the laws of Switzerland ("Holding"), and its wholly-owned subsidiary, Relief Therapeutics International SA, f/k/a Therametrics Discovery AG ("International", and collectively with Holding, "Relief"), on the other hand. NRx and Relief are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
SETTLEMENT AGREEMENTSettlement Agreement • May 1st, 2023 • NRX Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Settlement Agreement (including Exhibit A) (this “Settlement Agreement”) is made and entered into as of this 12th day of November, 2022 (the “Execution Date”), by and between Relief Therapeutics Holding AG and Relief Therapeutics International SA (together, "Relief"), on the one hand, and NEURORX, INC. ("NeuroRx") and NRX PHARMACEUTICALS, INC. ("NRx," and together with NeuroRx, the "NeuroRx Parties"), on the other hand. For all purposes, Relief and the NeuroRx Parties are each individually a "Party" and all are collectively the “Parties”).
